http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RS-52786-B

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_91f11da43226ef7f38b177dea8776cb4
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-03
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K5-1019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K4-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K7-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K4-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-03
filingDate 2007-07-19-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ae49bfb67af6f50f08efdd1086ec757b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ac37f10d54b59832ce5444ade552beaf
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6553264f31ca87f15c3cbfb1441ab27
publicationDate 2013-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber RS-52786-B
titleOfInvention PEPTIDES THAT HAVE PHARMACOLOGICAL ACTIVITY FOR THE TREATMENT OF DISEASES RELATED TO ALTERED CELL MIGRATION AS A CANCER
abstract Peptides and their functionally equivalent derivatives, in saline or unsalted form, of the general formula L1-X1-X2-X3-X4, in which: L1 is H, or acyl, X1 and X3, which are the same or different, optionally N-alkylated and / or Ca-alkylated, are selected from Arg, Orn and Lys, optionally guanidinyls, and phenylalanine substituted in the mat or para position with an amine or guanidine group; X2 is selected from Aib, Ac3c, Ac4c, Ac5c and Ac6c, optionally N-alkylated, X4 is selected from Phe, h-Phe, Tyr, Trp, 1-Nal, 2-Nal, h-1-Nal, h-2 -Nal, Cha, Chg and Phg, optionally amidized and / or Cα-alkylated. The application contains 8 more claims.
priorityDate 2006-08-09-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5234
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3520
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419559377
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID448670727
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6140
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419556475

Total number of triples: 35.